 KMTSJ, Inc.	DEPARTMENT:	Utilization Management
	SUBJECT:	Iron Infusions
	PRODUCT LINE:	All
	POLICY NUMBER:	UM122
	ORIGINAL POLICY EFFECTIVE DATE:	08/01/2020
	LAST REVISED DATE:	08/07/2021
	LAST REVIEWED DATE:	08/20/2023

SCOPE:

To ensure Group Health Cooperative of Eau Claire (the Cooperative) consistently and correctly administers benefits to all members according to their policy benefits.

POLICY:

It is the policy of the Cooperative to review requests for intravenous iron treatments according to member policy and evidence-based medical criteria through the prior authorization process.

PROCEDURE: Prior Authorization Required: YES

Coverage Criteria for Intravenous Iron Therapy

1. Documentation of a trial and failure of oral iron. (12 weeks) AND
2. Iron deficiency defined as a ferritin level <30 ng/mL or TSAT <15% (obtained within previous 30 days)

If criteria for coverage is met, the following considerations will be taken into account:

First line Treatments

Venofer® (iron sucrose)

- Only will be approved for members with documented **chronic kidney disease (CKD)** or **pregnancy**.

Ferrlecit® (ferric gluconate) Only will be approved for members with documented chronic kidney disease (CKD) who are **hemodialysis dependent**.


Second Line Treatments

Injectafer® (ferric carboxymaltose) **OR** Feraheme® (ferumoxytol)

Both approved for use in pregnancy.

Dosing IV Iron Agents

Medication	Dosing
Injectafer® (ferric carboxymaltose)	<ul style="list-style-type: none"> ▪ Weight ≥50 kg: Two doses of 750 mg, given seven or more days apart ▪ Weight <50 kg: Two doses of 15 mg/kg, given seven or more days apart
Feraheme® (ferumoxytol)	<ul style="list-style-type: none"> ▪ Two doses of 510 mg, given three to eight days apart
Venofer® (iron sucrose)	<ul style="list-style-type: none"> • <i>Hemodialysis-dependent chronic kidney disease:</i> 100 mg administered during consecutive dialysis sessions; the usual

 KMTSJ, Inc.	DEPARTMENT:	Utilization Management
	SUBJECT:	Iron Infusions
	PRODUCT LINE:	All
	POLICY NUMBER:	UM122
	ORIGINAL POLICY EFFECTIVE DATE:	08/01/2020
	LAST REVISED DATE:	08/07/2021
	LAST REVIEWED DATE:	08/20/2023

	<p>cumulative total dose is 1,000 mg (10 doses); may repeat treatment if clinically indicated.</p> <ul style="list-style-type: none"> <i>Peritoneal dialysis-dependent chronic kidney disease:</i> Two infusions of 300 mg administered 14 days apart, followed by a single 400 mg infusion 14 days later (total cumulative dose of 1,000 mg in 3 divided doses); may repeat treatment if clinically indicated. <i>Non-dialysis-dependent chronic kidney disease:</i> 200 mg administered on 5 different occasions within a 14-day period (total cumulative dose: 1,000 mg in 14-day period); may repeat treatment if clinically indicated. Note: Dosage has also been administered as 2 infusions of 500 mg on day 1 and day 14 (limited experience).
Ferrlecit® (ferric gluconate)	<ul style="list-style-type: none"> 125 mg (elemental iron) per dialysis session. For repletion treatment, most patients may require a cumulative dose of 1,000 mg (elemental iron) over ~8 dialysis sessions.

APPROVED: 

DATE: 08/20/2023

REVISION HISTORY:

Rev. Date	Revised By/Title	Summary of Revision
08/07/2021	Michele Bauer, MD, CMO	Updated the criteria.
08/25/2022	Michele Bauer, MD, CMO	Reviewed. No changes.
08/20/2023	Michele Bauer, MD, CMO	Reviewed. No changes.